Cargando…

Neoadjuvant immunotherapy of locoregionally advanced solid tumors

Definitive management of locoregionally advanced solid tumors presents a major challenge and often consists of a combination of surgical, radiotherapeutic and systemic therapy approaches. Upfront surgical treatment with or without adjuvant radiotherapy carries the risks of significant morbidities an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tarhini, Ahmad A, Eads, Jennifer R, Moore, Kathleen N, Tatard-Leitman, Valerie, Wright, John, Forde, Patrick M, Ferris, Robert L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Position Article and Guidelines
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386211/ https://www.ncbi.nlm.nih.gov/pubmed/35973745 http://dx.doi.org/10.1136/jitc-2022-005036

Ejemplares similares

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
por: Govindan, Ramaswamy, et al.
Publicado: (2022)

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
por: Rini, Brian I., et al.
Publicado: (2019)

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
por: Sullivan, Ryan J., et al.
Publicado: (2018)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
por: Cohen, Ezra E. W., et al.
Publicado: (2019)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie R., et al.
Publicado: (2018)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
por: Kelly, Ronan J, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
por: Rizvi, Naiyer, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
por: Silk, Ann W, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
por: Emens, Leisha A, et al.
Publicado: (2021)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
por: McNeel, Douglas G., et al.
Publicado: (2016)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
por: Kamat, Ashish M., et al.
Publicado: (2017)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
por: Shah, Nina, et al.
Publicado: (2020)

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy
por: Calderon, Moises A, et al.
Publicado: (2012)

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
por: Rini, Brian I., et al.
Publicado: (2016)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
por: Neelapu, Sattva S, et al.
Publicado: (2020)

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
por: Boyiadzis, Michael M, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
por: Greten, Tim F, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
por: Galsky, Matthew D, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
por: Disis, Mary L, et al.
Publicado: (2023)

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
por: Atkins, Michael B, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
por: Pavlick, Anna C, et al.
Publicado: (2023)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
por: Boyiadzis, Michael, et al.
Publicado: (2016)

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
por: Kluger, Harriet M., et al.
Publicado: (2020)

Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit
por: Pai, Sara, et al.
Publicado: (2020)

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies
por: Anderson, Kristin G, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
por: Maus, Marcela V, et al.
Publicado: (2020)

Allergen immunotherapy on the way to product-based evaluation—a WAO statement
por: Bachert, Claus, et al.
Publicado: (2015)

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
por: Hu-Lieskovan, Siwen, et al.
Publicado: (2020)

Z-DNA enhances immunotherapy by triggering death of inflammatory cancer-associated fibroblasts
por: Herbert, Alan, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
por: Kluger, Harriet, et al.
Publicado: (2023)

Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management
por: Naidoo, Jarushka, et al.
Publicado: (2020)

The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
por: Taube, Janis M, et al.
Publicado: (2020)

Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
por: Gonzalez-Cao, Maria, et al.
Publicado: (2021)

Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement
por: Tsimberidou, Apostolia M., et al.
Publicado: (2018)

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
por: Quinn, Casey, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges
por: Rutella, Sergio, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges
por: Cesano, Alessandra, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
por: Atkins, Michael B, et al.
Publicado: (2023)

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
por: Arnaldez, Fernanda I, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i6fl3qljjo0sbduuev87cdpgm1